HWKN

Hawkins, Inc. 10-Q Summary: Quarter Ended June 30, 2008

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended June 30, 2008, for Hawkins, Inc., a Minnesota-based company operating in three segments: Industrial, Water Treatment, and Pharmaceutical. The company manufactures and distributes chemical products, including bulk chemicals like caustic soda, antimicrobial products, and pharmaceutical ingredients. The filing is unaudited and should be read in conjunction with the fiscal year 2008 10-K.

Key Financial Metrics

Note: The company reported no long-term debt on the balance sheet as of June 30, 2008. Liquidity is supported by significant cash reserves and available-for-sale investments.

Material Changes vs. Prior Period

• Sales Growth: Sales increased 33.9% year-over-year, driven primarily by the Industrial segment (+40.7%) and Water Treatment segment (+26.1%). Growth was attributed to significant price increases to offset rising material costs and, to a lesser extent, volume increases.
• Margin Compression: Gross margin percentage declined from 24.3% to 21.9%. Management attributes a 2.5% reduction to a LIFO (Last-In, First-Out) charge resulting from rising raw material costs. Additionally, $694,527 in operating expenses were reclassified to Cost of Sales to better reflect their nature.
• Operating Efficiency: Selling, General, and Administrative (SG&A) expenses decreased as a percentage of sales (10.2% vs. 15.4%) due to the absence of one-time acquisition and ERP implementation costs incurred in the prior year.
• Segment Performance: The Industrial segment saw a significant jump in operating income ($2.6M increase), while the Pharmaceutical segment saw a slight decline in operating income due to FDA enforcement actions affecting compounding chemicals and increased lab testing expenses.

Guidance, Outlook, and Risks

• Capital Expenditures: The company plans to spend approximately $8.0 million on capacity expansion during the current fiscal year. This includes a $2.0 million acquisition of a facility in Centralia, Illinois, completed in July 2008, to expand lactate and food ingredient manufacturing.
• Liquidity: Management expects to fund working capital and capital investment needs through internally generated funds. No significant external financing is anticipated.
• Risks:
  • Commodity Prices: The company is subject to cyclical fluctuations in commodity chemical prices. While they attempt to pass costs to customers, there is no assurance this can be sustained.
  • Regulatory: The Pharmaceutical segment faces ongoing risks related to FDA enforcement discretion regarding compounding chemicals.
  • Investment Risk: The company holds fixed income securities subject to interest rate risk, though management intends to hold them to maturity/recovery.
• Unusual Items: The LIFO charge and the reclassification of $694,527 in expenses are non-recurring or accounting adjustments impacting the reported gross margin.

Investor Verification Checklist

• LIFO Impact: Verify the magnitude of the LIFO charge ($6.16M inventory reserve) and its sensitivity to future raw material price volatility.
• Expense Reclassification: Confirm the nature of the $694,527 reclassified from SG&A to Cost of Sales to ensure accurate margin trend analysis.
• Pharmaceutical Segment: Monitor the status of FDA enforcement actions and their potential long-term impact on the Pharmaceutical segment's revenue.
• Capital Allocation: Track the execution of the $8.0 million capacity expansion plan and the integration of the new Centralia, Illinois facility.
• Working Capital: Review the timing of inventory purchases and receivables collection, as these significantly impact quarterly operating cash flows due to the bulk nature of the business.